Welcome to our dedicated page for VivoSim Labs SEC filings (Ticker: VIVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VivoSim Labs, Inc. (VIVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed pharmaceutical and biotechnology services company, VivoSim Labs uses these filings to report on corporate governance, executive compensation, auditor ratification, board elections and other matters relevant to stockholders.
Core documents include annual proxy statements on Schedule 14A, where the company outlines items such as the election of directors, the ratification of its independent registered public accounting firm, advisory votes on executive compensation and the frequency of say‑on‑pay votes. These materials also summarize aspects of VivoSim Labs’ governance framework, including board composition, independence, committee structure and compensation practices.
Current reports on Form 8‑K provide timely disclosure of specific events, such as the appointment of key executives. For example, VivoSim Labs has filed an 8‑K describing the appointment of a Chief Commercial Officer, including information about the role, background and related compensatory arrangements. Another 8‑K reports the results of the company’s annual meeting of stockholders, detailing vote counts for director elections, auditor ratification and advisory proposals.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the outcomes of stockholder votes, changes in leadership roles and the structure of executive compensation without reading every page of the underlying filing. The page also surfaces Forms 10‑K and 10‑Q when available, along with Forms 4 and other ownership reports, enabling investors to review periodic reporting and insider transaction disclosures with AI‑generated highlights and context.
VivoSim Labs director David Gobel received 15,000 shares of common stock in the form of restricted stock units at no cost on January 27, 2026. These units will vest on the earlier of January 27, 2027 or the company’s next annual stockholder meeting, with potential acceleration if there is a change of control. After this award, Gobel beneficially owns 15,000 shares directly.
VivoSim Labs director Adam K. Stern received 15,000 shares of common stock on a restricted stock unit basis on January 27, 2026 at a price of $0.00 per share. These units vest on the earlier of January 27, 2027 or the next annual stockholder meeting, with possible acceleration upon a change of control. Following this award, Stern beneficially owns 19,899 shares directly. All share figures reflect a 1-for-12 reverse stock split of VivoSim Labs common stock that became effective on March 20, 2025.
VivoSim Labs, Inc. reported the results of its 2025 Annual Meeting of Stockholders. Of the 2,607,962 shares of common stock outstanding as of the October 17, 2025 record date, 972,769 shares, or 37.29%, were represented, satisfying the quorum requirement.
Stockholders elected Douglas Jay Cohen and David Gobel as Class II directors to serve until the 2028 annual meeting. They ratified Rosenberg Rich Baker Berman P.A. as independent registered public accounting firm for the fiscal year ending March 31, 2026, with 97.91% of votes cast in favor. On an advisory basis, stockholders approved executive compensation with 89.97% support and chose “one year” as the preferred frequency for future advisory votes on executive pay, with 97.17% of votes cast supporting annual votes. The company will hold these advisory votes on an annual basis going forward.
VivoSim Labs, Inc. (VIVS) filed a Form 4 reporting a director’s change in ownership. On 11/17/2025, the director reported a transaction involving 3,266 shares of common stock at $2.2351 per share, and reported 0 shares beneficially owned following the transaction, held directly.
The company notes that, effective March 20, 2025, it completed a 1-for-12 reverse stock split of its common stock, and all share amounts in this filing already reflect that split.
VivoSim Labs (VIVS) filed its Q2 FY2026 10‑Q, reporting a net loss of $2.545 million for the quarter ended September 30, 2025, on $28,000 in royalty revenue. Operating expenses totaled $2.663 million, led by research and development of $923,000 and selling, general and administrative of $1.740 million. Other income contributed $92,000.
Liquidity remains tight. Cash and cash equivalents were $6.677 million with total assets of $9.686 million and stockholders’ equity of $7.065 million. Net cash used in operating activities was $6.318 million for the six months. The company raised approximately $1.8 million during the six months via its ATM, issuing 701,729 shares. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
During March 2025, the company sold its FXR program for $10.0 million (with $1.0 million in escrow and potential milestones up to $50.0 million). As of November 1, 2025, 2,607,962 shares were outstanding. The company recorded a $0.6 million accrual related to an ongoing legal matter.
VivoSim Labs filed its definitive proxy for the 2025 Annual Meeting, to be held virtually on December 16, 2025 at 9:00 a.m. Pacific. Stockholders can attend, ask questions, and vote via webcast at www.virtualshareholdermeeting.com/VIVS2025.
Four items are up for vote: elect two Class II directors (Douglas Jay Cohen and David Gobel) to terms expiring in 2028; ratify Rosenberg Rich Baker Berman P.A. as independent auditor for the fiscal year ending March 31, 2026; approve, on an advisory basis, named executive officer compensation; and approve, on an advisory basis, holding the say‑on‑pay vote every one year. The Board recommends FOR all proposals and “ONE YEAR” on frequency.
The record date is October 17, 2025, with 2,607,962 shares of common stock outstanding. A quorum requires the presence, in person or by proxy, of 869,321 shares, representing one‑third of shares entitled to vote. Fiscal 2025 audit fees billed by RRBB P.A. totaled $260,000.
VivoSim Labs, Inc. filed an S-8 registration statement to register securities under its employee benefit plan. The filing notes a 1-for-12 reverse stock split effected March 20, 2025, and incorporates by reference the company’s recent Annual Report (fiscal year ended March 31, 2025) and certain subsequent Current Reports and Quarterly Report. The exhibit list includes amended charters and bylaws, the Amended and Restated 2022 Equity Incentive Plan and award agreement forms, legal opinion and auditor consent. The filing is signed by senior officers on August 28, 2025.
VivoSim Labs, Inc. reported an equity award to its Chief Commercial Officer, Lialin Tony Serge. The filing shows an option to purchase 40,000 shares of common stock with an exercise price of $1.78 each, exercisable beginning 08/11/2025 and expiring 08/11/2035. The option vests over four years with 25% vesting on 08/11/2026 and the remainder vesting in 12 equal quarterly installments thereafter. Following the grant the reporting person beneficially owns 40,000 options on a direct basis.